Peptides DB
Research-centric peptide and protocol reference hub
Study 22 of 22PT-141 (Bremelanotide) literatureUrology · RCT2005

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

Co-administration of intranasal PT-141 and sildenafil may enhance erectile response in men who do not adequately respond to sildenafil alone.

Read at UrologyAdd to compare

Where it sits

this study against the rest of the pt-141 (bremelanotide) corpus
6
Preclinical
6
Observational
0
Open-label
3
Randomised · this one
7
Reviews

Summary and findings

This study evaluated the safety and pharmacodynamic effect of co-administering 7.5 mg intranasal PT-141 and 25 mg sildenafil in 19 men with erectile dysfunction. The results indicated that the combination led to a greater erectile response compared to sildenafil alone. No new adverse events were reported.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Erectile response significantly greater with PT-141 and sildenafil vs sildenafil alone, p<0.05.2005

Abstract

The authors’ words, as Urology supplied them

<h4>Objectives</h4>To evaluate the safety and pharmacodynamic effect of co-administration of subtherapeutic doses of PT-141, a cyclic heptapeptide melanocortin analogue, and sildenafil to patients with erectile dysfunction.<h4>Methods</h4>Nineteen patients with erectile dysfunction who were responders to either Viagra or Levitra by self-report were given 25 mg sildenafil and 7.5 mg intranasal PT-141, 25 mg sildenafil and an intranasal placebo spray, and a placebo tablet and an intranasal placebo spray in a randomized cross-over design. Erectile activity in response to two 30-minute episodes of visual sexual stimulation was assessed by RigiScan during a 6-hour postdose period.<h4>Results</h4>The erectile response induced by co-administration of PT-141 and sildenafil was significantly greater than the response elicited by administration of sildenafil alone. Co-administration of PT-141 and sildenafil was safe and well-tolerated and did not result in new adverse events or adverse events that were increased in frequency or severity compared with monotherapy.<h4>Conclusions</h4>Co-administration of intranasal PT-141 and a phosphodiesterase type 5 inhibitor may constitute a treatment alternative for patients in whom higher doses of a single therapy are not effective or well tolerated.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the PT-141 (Bremelanotide) corpus

DPeptides for male sexual dysfunction: a systematic review of emerging evidence.The journal of sexual medicine · 2026 · Not reported in abstract.reviewDMultifunctional material platforms for neural interfaces: active orchestration of dynamic foreign body response across implantation lifetimes.Bioactive materials · 2026reviewBAn interpretable machine learning model for predicting febrile seizures following enterovirus infection in children.Annals of medicine · 2026 · n=446 · XGBoost model training set AUC was 0.972 (95% CI: 0.958-0.987).HumanDReal-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026reviewDSmart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.Bioactive materials · 2026reviewAHMB supplementation combined with high-intensity functional exercise supports aerobic capacity but not strength in trained and untrained males: a randomized controlled trial.Journal of the International Society of Sports Nutrition · 2026 · n=90 · VO2MAX increased with HMB in TR, p=0.024.Human